Nearly all children and adolescents with immune-mediated thrombotic thrombocytopenic purpura (iTTP) achieved a clinical response with Cablivi (caplacizumab-yhdp), according to a medical records review. In this study, clinical response was defined as a normal platelet count and a drop in lactate dehydrogenase (LDH), a marker of tissue damage, for…